Allergan, Inc.

Allergan Sales, Inc.

Other

Palomar Medicaltechnologies, Inc.

James A Burke

Larry Allen Wheeler

Michael E Garst

Patrick Michael Hughes

Michael R Robinson

Glenn T Huang

Ton Lin

Rosy Sheng Donn

Stephen A Munk

Kai-Ming Zhang

Brittany A Jackson

Charles Gluchowski

Rhett M Schiffman

Alazar N Ghebremeskel

Scott M Whitcup

Wendy M Blanda

Ken Chow

Daniel W Gil

Richard S Graham

Robert T Lyons

Dale A Harcourt

Werhner C Orilla

Corine Ghosn

Alexandra Almazan

Michael Engles

Lakshmi Rajagopalan

James Nienyuan Chang

Gregory B Altshuler

Todd M Heidelbaugh

Orest Olejnik

Lon T Spada

Joan-En Chang-Lin

Dario G Gomez

Christopher Gaal

Ilya Yaroslavsky

Robert R Lopez

Andrei V Erofeev

Zoran Novakovic

Hui Liu

Ronald K Lai

Orilla C Werhner

Maria Escobar

Cindy W Wu

Rosy Sheng

Kun Xu

Marianne M Do

Henry H Zenzie

Patric M Hughes

Ruwen Shi

Orilla Werhner

Disclosed are antiseptic compositions for disinfecting tissues, in particular for ocular use. Methods and compositions disclosed herein include sodium chlorite, optionally in combination with a surfactant.

Sodium chlorite compositions with enhanced antimicrobial efficacy and reduced toxicity

Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity

Biodegradable drug delivery systems, such as extruded implants, for the sustained delivery of a protein to an ocular region of the eye or intraarticular region in the body are described. The drug delivery systems may be used to treat a variety of ocular and medical conditions, including macular degeneration. Methods for using and making the drug delivery systems are also described. The drug delivery systems can be in the form of extruded filaments configured for placement in an ocular region such as the vitreous body or anterior chamber of the eye.

Biodegradable drug delivery systems for the sustained release of proteins

Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Method for treating atrophic age related macular degeneration

Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.

Intracameral sustained release therapeutic agent implants

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

Sustained release intraocular implants and methods for treating ocular vasculopathies

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

Compositions and methods for localized therapy of the eye

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like.

Sustained release intraocular implants and methods for preventing retinal dysfunction

A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.

Biodegradable drug delivery system

Compositions and methods for treating dry age related macular degeneration (dry AMD) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).

Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure.

Growing community of inventors

Santa Ana, CA, United States of America

James A Burke